The family of a Nova Scotia girl diagnosed with a rare genetic disorder is optimistic about her future for the first time. Eight-year-old Harper Tanton will soon participate in a clinical trial for children with CTNNB1 syndrome, making her the fourth child globally to do so. Harper, who heavily relies on a wheelchair and faces developmental and speech delays, has been at the center of her family’s quest for answers regarding her condition.
Harper’s mother, Tara Tanton, shared the challenges they faced, noting that early predictions suggested Harper would never walk or talk. Despite an initial misdiagnosis of cerebral palsy, genetic testing eventually revealed CTNNB1 syndrome, a rare gene mutation affecting protein production critical for development. With fewer than 40 known cases in Canada, the disorder was previously deemed incurable due to limited pharmaceutical interest.
The Tanton family’s journey led them to the CTNNB1 Foundation in Slovenia, founded by Spela Mirosevic and her husband after their son’s diagnosis in 2021. The foundation, supported by community fundraising efforts, focuses on gene replacement therapy to potentially halt or cure CTNNB1 syndrome. The therapy, inspired by treatments for other conditions, has shown promising results in initial trials.
Harper is set to undergo the procedure in the upcoming months, with expectations of improved physical and mental development. While the estimated cost is significant at $300,000, the family remains determined, supported by community initiatives and the foundation’s coverage of therapy expenses. Regular assessments and follow-up visits to Slovenia will be part of the trial process.
The Tantons are hopeful that Harper’s participation in the trial will not only benefit her but also inspire others facing rare diseases. Despite the challenges and sacrifices involved, they remain cautiously optimistic about the potential outcomes and are committed to providing the best possible future for Harper.